Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

New Therapeutic Schedule for Prostatic Cancer-3 Cells with ET-1 RNAi and Endostar

  • Zhang, Hao-Jie (Department of Urology Surgery, Huadong Hospital Affiliated To Fudan University) ;
  • Qian, Wei-Qing (Department of Urology Surgery, Huadong Hospital Affiliated To Fudan University) ;
  • Chen, Ran (Department of Urology Surgery, Huadong Hospital Affiliated To Fudan University) ;
  • Sun, Zhong-Quan (Department of Urology Surgery, Huadong Hospital Affiliated To Fudan University) ;
  • Song, Jian-Da (Department of Urology Surgery, Huadong Hospital Affiliated To Fudan University) ;
  • Sheng, Lu (Department of Urology Surgery, Huadong Hospital Affiliated To Fudan University)
  • Published : 2015.01.06
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Endothelin-1 and Endostar are both significant for the progression, proliferation, metastasis and invasion of cancer. In this paper, we studied the effect of ET-1 RNAi and Endostar in PC-3 prostatic cancer cells. Materials and Methods: The lentiviral vector was used in the establishment of ET-1 knockdown PC-3 cells. Progression and apoptosis were assessed by CKK-8 and flow cytometry, respectively. Transwell assay was used to estimate invasion and signaling pathways were studied by Western blotting. Results: ET-1 mRNA and protein in ET-1 knockdown PC-3 cells were reduced to 26.4% and 22.4% compared with control group, respectively. ET-1 RNAi and Endostar both were effective for the suppression of progression and invasion of PC-3 cells. From Western blotting results, the effects of ET-1 regulation and Endostar on PC-3 cells were at least related to some signaling pathways involving PI3K/Akt/Caspase-3, Erk1/2/Bcl-2/Caspase-3 and MMPs (MMP-2 and MMP-9). Furthermore, combined treatment of ET-1RNAi and Endostar was found to be more effective than single treatment. Conclusions: Both ET-1 RNAi and Endostar can inhibit the progression and invasion of PC-3 cells, but combined treatment might be a better therapeutic schedule.

Keywords

References

  1. Ali H, Loizidou M, Dashwood M, et al (2000). Stimulation of colorectal cancer cell line growth by ET-1 and its inhibition by ET (A) antagonists. Gut, 47, 685-8. https://doi.org/10.1136/gut.47.5.685
  2. Bagnato A, Rosano L (2012). Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis. Curr Oncol, 19, 36-8.
  3. De Jesus-Gonzalez N, Robinson E, Penchev R, et al (2012). Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens, 25, 1118-6. https://doi.org/10.1038/ajh.2012.97
  4. Dhanabal M, Ramchandran R, Waterman MJ, et al (1999). Endostatin induces endothelial cell apoptosis. J Biol Chem, 274, 11721-6. https://doi.org/10.1074/jbc.274.17.11721
  5. Dong X-P, Xiao T-H, Dong H, et al (2013). Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice. APJCP, 14, 3079-5.
  6. Fiorentini C, Bodei S, Bedussi F, et al (2014). GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Exp Cell Res, 323, 100-11. https://doi.org/10.1016/j.yexcr.2014.02.025
  7. Folkman J (2006). Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Exp Cell Res, 312, 594-14. https://doi.org/10.1016/j.yexcr.2005.11.015
  8. Ha NH, Nair VS, Reddy DN, et al (2011). Lactoferrinendothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res, 71, 7259-11. https://doi.org/10.1158/0008-5472.CAN-11-1143
  9. Hinsley EE, Kumar S, Hunter KD, et al (2012). Endothelin-1 stimulates oral fibroblasts to promote oral cancer invasion. Life Sci, 91, 557-5. https://doi.org/10.1016/j.lfs.2012.04.001
  10. Hsu JY, Pfahl M (1998). ET-1 expression and growth inhibition of prostate cancer cells: a retinoid target with novel specificity. Cancer Res, 58, 4817-6.
  11. Irani S, Salajegheh A, Smith RA, et al (2014). A review of the profile of endothelin axis in cancer and its management. Crit Rev Oncol Hematol, 89, 314-21. https://doi.org/10.1016/j.critrevonc.2013.08.011
  12. Johan Dixelius, Helena Larsson, Takako Sasaki, et al (2000). Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood, 95, 3403-11.
  13. Kalles V, Zografos GC, Provatopoulou X, et al (2012). Circulating levels of endothelin-1 (ET-1) and its precursor (Big ET-1) in breast cancer early diagnosis. Tumour Biol, 33, 1231-6. https://doi.org/10.1007/s13277-012-0371-x
  14. Kim YM, Jang JW, Lee OH, et al (2000). Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res, 60, 5410-3.
  15. Leon J, Casado J, Jimenez Ruiz SM, et al (2014). Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NFkappabeta. J Pineal Res, 56, 415-12. https://doi.org/10.1111/jpi.12131
  16. Li Z, Zhang LJ, Zhang HR, et al (2014). Tumor-derived transforming growth factor-${\beta}$ is critical for tumor progression and evasion from immune surveillance. Asian Pac J Cancer Prev, 15, 5181-6. https://doi.org/10.7314/APJCP.2014.15.13.5181
  17. Ling L, Maguire JJ, Davenport AP (2013). Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer. Br J Pharmacol, 168, 283-13. https://doi.org/10.1111/j.1476-5381.2011.01786.x
  18. Ling Y, Yang Y, Lu N, et al (2007). Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun, 361, 79-6. https://doi.org/10.1016/j.bbrc.2007.06.155
  19. Liu C, Xu P, Chen D, et al (2013). Roles of autophagy-related genes Beclin-1 and LC3 in the development and progression of prostate cancer and benign prostatic hyperplasia. Biomed Rep, 1, 855-60.
  20. Lu N, Ling Y, Gao Y, et al (2008). Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp Biol Med (Maywood), 233, 1013-8. https://doi.org/10.3181/0801-RM-7
  21. Maffei R, Bulgarelli J, Fiorcari S, et al (2014). Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. PLoS One, 9, 1-13.
  22. Meimei Liu, Peiling Li, Sui. L (2007.). Inhibition of endostatin on growth of ovarian cancer cell line SKOV3. Basic&Clinical Medicine, 27, 772-5.
  23. Ni Q, Ji H, Zhao Z, et al (2009). Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism. Eur J Pharmacol, 614, 1-6. https://doi.org/10.1016/j.ejphar.2009.04.032
  24. Nyberg P, Heikkila P, Sorsa T, et al (2003). Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem, 278, 22404-8. https://doi.org/10.1074/jbc.M210325200
  25. O'Reilly MS, Boehm T, Shing Y, et al (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-9. https://doi.org/10.1016/S0092-8674(00)81848-6
  26. Puzovic V, Brcic I, Ranogajec I, et al (2014). Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients. Neoplasma, 61, 439-9. https://doi.org/10.4149/neo_2014_054
  27. Rosano L, Spinella F, Bagnato A (2013). Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer, 13, 637-15. https://doi.org/10.1038/nrc3546
  28. Rotondo S, Menard J, Durlach A, et al (2012). Endothelin-1 and receptor A: predictive value for biochemical relapse on patients with advanced and metastatic prostate cancer. Prog Urol, 22, 38-7. https://doi.org/10.1016/j.purol.2011.08.038
  29. Shao N, Wang Y, Jiang WY, et al (2013). Immunotherapy and endothelin receptor antagonists for treatment of castrationresistant prostate cancer. Int J Cancer, 133, 1743-8. https://doi.org/10.1002/ijc.28162
  30. Spinella F, Caprara V, Cianfrocca R, et al (2014). The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis, 35, 840-8. https://doi.org/10.1093/carcin/bgu018
  31. Stassi G, Todaro M, Zerilli M, et al (2003). Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res, 63, 6784-7.
  32. Sudhakar A, Sugimoto H, Yang C, et al (2003). Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA, 100, 4766-6. https://doi.org/10.1073/pnas.0730882100
  33. Szarvas T, Laszlo V, Vom Dorp F, et al (2012). Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer. Int J Cancer, 130, 2922-9. https://doi.org/10.1002/ijc.26343
  34. Tamkus D, Sikorskii A, Gallo KA, et al (2013). Endothelin-1 enriched tumor phenotype predicts breast cancer recurrence. ISRN Oncol, 2013, 385-14.
  35. Te Velde EA, Reijerkerk A, Brandsma D, et al (2005). Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br J Cancer, 92, 729-7. https://doi.org/10.1038/sj.bjc.6602385
  36. Wang R, Lohr CV, Fischer K, et al (2013a). Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer. Int J Cancer, 132, 1004-9. https://doi.org/10.1002/ijc.27762
  37. Wang YB, Liu JH, Song ZM (2013b). Effects of recombinant human endostatin on the expression of vascular endothelial growth factor in human gastric cancer cell line MGC-803. Biomed Rep, 1, 77-3.
  38. Wang YB, Liu JH, Song ZM (2013c). Effects of recombinant human endostatin on the expression of vascular endothelial growth factor in human gastric cancer cell line MGC-803. Biomed Rep, 1, 77-9.
  39. Wei HM, Qin SK, Yin XJ, et al (2010). Therapeutic features of endostar, a modified endostatin, on ascites tumor in mice. Nan Fang Yi Ke Da Xue Xue Bao, 30, 1509-5 (in Chinese).
  40. Wu X, Zheng J, Zhu J, et al (2001). Inhibitory effect of antisense VEGF121 and endostatin genes transfection on tumor growth and metastasis of human giant cell lung cancer. Zhongguo Fei Ai Za Zhi, 4, 83-7.
  41. Wynder EL, Mabuchi K, Whitmore WF, Jr. (1971). Epidemiology of cancer of the prostate. Cancer, 28, 344-17. https://doi.org/10.1002/1097-0142(197108)28:2<344::AID-CNCR2820280214>3.0.CO;2-#
  42. Xu YF, Zhu LP, Hu B, et al (2007). A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther, 14, 151-7. https://doi.org/10.1038/sj.cgt.7701003
  43. Xue xue, Song You, Liang. X (2010). Chemotherapertic resistance of cancer and its related gene therapeutic drugs. Chinese J Med Chem, 20, 460-7.
  44. Yokoyama Y, Ramakrishnan S (2007). Binding of endostatin to human ovarian cancer cells inhibits cell attachment. Int J Cancer, 121, 2402-9. https://doi.org/10.1002/ijc.22935
  45. Zhang L-P, Liao X-Y, Xu Y-M, et al (2013). Efficacy and safety of $endostar^{(R)}combined$ with chemotherapy in patients with advanced soft tissue sarcomas. Asian Pac J Cancer Prev, 14, 4255-5. https://doi.org/10.7314/APJCP.2013.14.7.4255
  46. Zhang Y, Ge W, Zhao J, et al (2009). The effect of endostatin and radiotherapy on human lung cancer cell line a549 and the impact of hif-1 expression after therapy. Zhongguo Fei Ai Za Zhi, 12, 33-7.
  47. Zhou WQ, Yin HL, Zhang ZY, et al (2008). Expression of VEGF in prostate cancer and its correlation with ET-1. Zhonghua Nan Ke Xue, 14, 987-6.

Cited by

  1. TGF-β induces HLA-G expression through inhibiting miR-152 in gastric cancer cells vol.22, pp.1, 2015, https://doi.org/10.1186/s12929-015-0177-4